DNA-based drug interactions of cisplatin

Cancer Treatment Reviews

Volumn 28, Issue 6, 2002, Pages 291-303

  Crul, M ^a,b   van Waardenburg, R C A M ^a,c   Beijnen, J H ^b,d   Schellens, J H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; BLEOMYCIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NEDAPLATIN; NOVOBIOCIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TENIPOSIDE; THIOUREA; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CELL TYPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA REPAIR; DNA SEQUENCE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DNA INTERACTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; OVARY CANCER; REVIEW; TESTIS CANCER;

EID: 0036926578     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00093-2     Document Type: Review

References (96)

1. Loehrer S, Einhorn ADJ. Diagnosis and treatment: drugs five years later: Cisplatin. Ann Int Med 1984; 100: 704-713.
2. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-790.
3. Roberts JM, Knox RJ, Friedlos F, Lydall DA. DNA as the target for the cytotoxic and anti-tumour action of platinum coordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In: McBrien DCH, Slater TF (eds.), Biochemical Mechanisms of Platinum Antitumour Drugs. IRL Press: Oxford, 1986; 29.
4. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987; 34: 155-166.
5. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275-280.
6. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-1176.
7. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995; 55: 474-477.
8. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-220.
9. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.
10. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20: 435-439.
11. Johnson SW, Perez RP, Godwin AK, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 1994; 47: 689-697.
12. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996; 271: 8285-8294.
13. Sancar A. DNA excision repair. Ann Rev Biochem 1996; 65: 43-81.
14. Friedberg EC. Relationships between DNA repair and transcription. Ann Rev Biochem 1996; 65: 15-42.
15. Paques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in saccharomyces cerevisiae. Microbiol Mol Biol Rev 1999; 63: 349-404.
16. Crul M, Schellens JHM, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997; 23: 341-366.
17. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1998; 6: 1653-1664.
18. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Sem Oncol 1990; 17(5 suppl. 8): 3-17.
19. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-8925.
20. Etienne MC, Bernard S, Fischel JL, et al. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 1991; 63: 372-377.
21. Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988; 21: 237-240.
22. Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52: 6501-6506.
23. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996; 32A: 2148-2154.
24. Tanaka T, Masuda H, Naito M, Tamai H. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Anticancer Res 2001; 21: 2463-2469.
25. Fujishima H, Nakano S, Masumoto N, et al. Inhibition by 5-fluorouracil of ERCC1 and γ-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 1997; 9: 167-172.
26. Zaffaroni N, Orlandi L, Gornati D, De Marco C, Vaglini M, Silvestrini R. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. Eur J Cancer 1996; 32A: 1766-1773.
27. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995; 47: 1072-1079.
28. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol 1997; 52: 798-806.
29. Li L, Liu X, Glassman AB, et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997; 57: 1487-1494.
30. Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho DH. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 1981; 41: 25-30.
31. Berek JS, Schink JC, Knox RM. Synergistic effect of combined intraperitoneal cisplatin and cytosinearabinoside in a murine ovarian cancer model. Obstet Gynecol 1989; 74: 663-666.
32. Spriggs DR, Robbins G, Kufe DW. Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity Of 1-β-D-arabinofuranosylcytosine. Biochem Pharmacol 1986; 35: 4297-4302.
33. Fram RJ, Robichaud N, Bishov SD, Wilson JM. Interactions of cis-diamminedichloroplatinum (II) with 1-β-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 1987; 47: 3360-3365.
34. Rauko P, Novotny L, Reichelova V, Balazova E. Evaluation of synergism of drugs cis-diamminedichloroplatinum (II) and arabinosylcytosine on the level of chemical interaction with DNA and on the growth of mouse leukemia. Gen Pharmacol 1991; 22: 805-810.
35. Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fisher RI, Erickson LC. 1-β-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum (II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 1989; 49: 1383-1389.
36. Ellerhorst JA, Frost P, Abbruzzese JL, Newman RA, Chernajovsky Y. 2′-Deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 1993; 67: 209-215.
37. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-530.
38. van Moorsel CJA, Pinedo HM, Veerman G, et al. Mechanism of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999; 80: 981-990.
39. Theodossiou C, Cook JA, Fisher J, et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825-832.
40. Voigt W, Bulankin A, Muller T, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cells. Clin Cancer Res 2000; 6: 2087-2093.
41. van Moorsel CJA, Pinedo HM, Smid K, et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420-2429.
42. v Moorsel CJA, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10: 441-448.
43. Crul M, Schoemaker NE, Pluim D, et al. Phase I/II clinical and pharmacokinetic study of dose-intensive cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer. Br J Clin Pharmacol, in press.
44. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6: 773-781.
45. van Moorsel CJA, Lakerveld B, Smid K, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin sensitive or resistant human ovarian cancer cell lines, submitted.
46. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991; 52: 35-84.
47. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-1703.
48. Parker R, Lee KB, Dabholkar M, Bostick-Bruton F, Simms M, Reed E. Influence of taxol: Cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 1993; 34: 356 (abs).
49. Kamazawa S, Kigawa J, Minagawa Y, et al. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 2000; 59: 329-335.
50. de Graaff M, Maliepaard M, Pluim D, Floot BJ, Slaper-Cortenbach IC, Schellens JH. In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM. Anticancer Drugs 1999; 10: 213-218.
51. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 1999; 79:286-292.
52. Pronk LC, Schellens JH, Planting AS, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-1079.
53. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/II study in solid tumor patients. Proc Am Assoc Clin Oncol 1994; 13: 132 (abs).
54. Ma J, Verweij J, Planting AST, et al. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 1996; 37: 382-384.
55. Eng WK, Faucette L, Johnson RK, et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34: 755-760.
56. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-5082.
57. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996; 14: 2345 2352.
58. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-2096.
59. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14:3056-3061.
60. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998; 16: 2233-2237.
61. Bookman MA, Malmstrom. H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352.
62. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
63. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
64. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994; 6: 269-279.
65. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
66. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-741.
67. Jonsson E, Fridborg EH, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998; 54: 509-514.
68. Janss AJ, Cnaan A, Zhao H, et al. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anti-Cancer Drugs 1998; 9: 641-652.
69. Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41: 307-316.
70. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998; 41: 385-390.
71. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-3084.
72. De Jonge MJA, Loos WJ, Gelderblom H, et al. Phase I pharmacological study of oral topotecan and intravenous cisplatin: sequence dependent hematologic side effects. J Clin Oncol 2000; 18: 2104-2115.
73. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-610.
74. Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56: 789-793.
75. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y. Inhibition of cis-diamminedichloroplatinum (II) induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous carcinoma cells. Int J Cancer 1995; 62: 70-75.
76. Masuda M, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777-782.
77. De Jonge MJA, Verweij J, Planting AST, et al. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. Clin Cancer Res 1999; 5:2012-2017.
78. De Jonge MJA, Verweij J, de Bruijn P, et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 2000; 18: 195-203.
79. Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 1996; 2: 687-693.
80. Bendixen C, Thomsen B, Alsner J, Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 1990; 29: 5613-5619.
81. Zeghari-Squalli N, Raymond E, Cvitokovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999; 5: 1189-1196.
82. Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 2001; 7: 202-209.
83. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 2002; 277: 1255-1260.
84. Van Waardenburg RCAM, de Jong LA, van Delft F, et al. The homologous recombination pathway is essential for the synergistic cytotoxicity between cisplatin and topoisomerase I inhibitors in lower and higher eukaryotes. Proc Am Assoc Cancer Res 2001; 42: 3582 (abs).
85. Van Waardenburg RCAM, de Jong LA, Maliepaard M, Verseyden C, Pluim D, Schellens JHM. Synergistic cytotoxicity between platinum drugs and topoisomerase I inhibitors is induced by direct interaction between topoisomerase I and platinum-DNA adducts, submitted.
86. Ross WE. DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 1985; 34: 4191-4195.
87. Katz EJ, Vick JS, Kling KM, Andrews PA, Howell SB. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 1990; 26: 724-727.
88. Eder JP, Teicher BA, Holden SA, Senator L, Cathcart KNS, Schnipper LE. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichlorplatinum (II) in chinese hamster ovary cells and in an epipodophyllotoxin resistant subline. Cancer Chemother Pharmacol 1990; 26: 423-428.
89. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 1993; 53: 5663-5668.
90. Adjei AA, Budihardjo II, Rowinsky EK, et al. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res 1997; 3: 761-770.
91. Ellis GK, Crowley J, Livingston RB, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer 1991; 67: 2969 2973.
92. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res 1991; 51: 510-513.
93. Sibghatullah, Husain I, Carlton W, Sancar A. Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nucleic Acids Res 1989; 17: 4471-4484.
94. Larminat F, Bohr VA. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 1994; 22: 3005 3010.
95. Schellens JH, Ma J, Planting AS, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73: 1569-1575.
96. Abratt RP, Sandler A, Crino L, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Sem Oncol 1998; 25: 35-43.